Pharmaceutical translation services in Belgium for FAMHP and EMA submissions

Patient leaflets, SmPCs, clinical trial documents and pharmacovigilance reports, translated by specialists

Pharmaceutical translation in Belgium for FAMHP and EMA: PILs, SmPCs, clinical trials and pharmacovigilance reports, by specialised native-language translators.

Pharmaceutical translation for clinical trials, patient information leaflets and summaries of product characteristics, by specialised native-language translators.

Pharmaceutical documents from clinical trial to market authorisation

Pharmaceutical documents are among the most consequential texts a translation agency handles. A submission to the European Medicines Agency, a clinical trial protocol, a patient information leaflet or a labelling file each carries regulatory and safety implications that tolerate no approximation.

The terminology must be correct. The format must comply with the applicable guideline. The translation must be verifiable.

Read moreShow less

Pharmaceutical translation in Belgium operates within a dense regulatory framework: the Federal Agency for Medicines and Health Products (FAMHP/AFMPS), the European Medicines Agency (EMA), ICH guidelines, EU Clinical Trials Regulation (CTR 536/2014) and the MDR 2017/745 for pharmaceutical-adjacent medical devices.

Every document must reflect the terminology validated by the relevant regulator, in the language it will be submitted in. BeTranslated, a specialised translation agency with a business office in Liège, structures each pharmaceutical translation project around these regulatory requirements.

Why pharmaceutical translation requires specialist expertise

Regulatory terminology is not optional

The EMA and FAMHP publish approved terminology for pharmacological concepts, dosing instructions, adverse event reporting and safety terminology in each of the EU’s official languages. A translation that deviates from this approved terminology, even subtly, may be returned for revision, which can delay a submission.

Read moreShow less

The EMA and FAMHP publish approved terminology for pharmacological concepts, dosing instructions, adverse event reporting and safety terminology in each of the EU’s official languages.

A translation that deviates from this approved terminology, even subtly, may be returned for revision, which can delay a submission. The translator must know not only the language but the exact terms that the regulator expects to see in each section of the dossier.

Patient safety starts with clear communication

Patient information leaflets (PILs) and summary of product characteristics (SmPCs) are read by pharmacists, healthcare professionals and patients who act on them directly.

A misrendered dosing instruction, a confusingly translated contraindication or an unclear adverse event description can contribute to medication errors.

Read moreShow less

Belgium’s obligations under Directive 2001/83/EC require that PILs be legible, understandable and written in the official language of the member state where the product is marketed.

Pharmaceutical documents we translate

  • Marketing authorisation applications (CTD, Common Technical Document)
  • Clinical trial protocols and amendments (EudraCT, CTR)
  • Informed consent forms and participant information sheets
  • Pharmacovigilance reports (PSUR, DSUR, SUSAR, PADER)
  • Patient information leaflets (PILs) and summaries of product characteristics (SmPCs)
  • Labelling and packaging text in compliance with Annex II formats
  • Regulatory correspondence with the FAMHP and the EMA
  • Clinical study reports (CSR) submitted to regulatory bodies
  • Quality and manufacturing documentation (GMP, validation reports)

Belgium has a large pharmaceutical sector, with Janssen Pharmaceutica, UCB, Galapagos, GSK Vaccines and Pfizer among the companies with Belgian operations

Read moreShow less

Major players including Janssen Pharmaceutica (Johnson & Johnson), UCB, Galapagos, GSK Vaccines and Pfizer all have significant Belgian operations.

Each clinical trial conducted in Belgium, each product authorised by the FAMHP, and each label printed for the Belgian market generates pharmaceutical documentation that must be translated accurately into the relevant official languages.

Three languages, three regulatory audiences

Products marketed in Belgium must carry labelling and product information in French, Dutch and German. For clinical trial submissions under the EU CTR, the trial protocol and consent forms must be translated into the language of each participating member state.

Managing this multilingual obligation for a multinational trial or a Belgian licensing dossier requires a translation partner with both language coverage and regulatory expertise.

Pharmaceutical documents by stage, as listed on this page
StageDocuments named on this page
Marketing authorisationMarketing authorisation applications (CTD, Common Technical Document)
Clinical trialsProtocols and amendments (EudraCT, CTR), informed consent forms, participant information sheets, clinical study reports
SafetyPharmacovigilance reports (PSUR, DSUR, SUSAR, PADER)
Product informationPatient information leaflets (PILs), summaries of product characteristics (SmPCs), labelling and packaging text
Regulators and qualityCorrespondence with the FAMHP and the EMA; quality and manufacturing documentation

How BeTranslated handles pharmaceutical translation

Specialised native-language translators

Pharmaceutical files go to specialised native-language translators. All translate into their mother tongue. Read more on our professional translators page.

Independent review and confidentiality

Every pharmaceutical translation undergoes independent proofreading by a second specialist. Confidential clinical data and unpublished compound information are handled under strict non-disclosure agreements and in line with the GDPR. Rates are quoted in a detailed proposal before project launch.

Read moreShow less

A regulatory dossier, PIL or clinical trial document to translate?

Request a quote with your files. A specialist project manager responds within 2 hours during working hours.

Protect your regulatory submissions with specialist expertise

The terms of the trade checked, line by line

Whether you are a regulatory affairs manager preparing a CTD submission, a clinical operations director running a Belgian trial site or a medical writer producing a CSR, the quality of your pharmaceutical translation has direct consequences for the regulatory timeline and the safety of the patients your product is designed to serve.

To start your project:

  • Email hello@betranslated.be

Language combinations available in French, Dutch, German, English and all other languages on the languages page.

Questions about pharmaceutical translation in Belgium

Which languages must a medicine’s information be in for Belgium?

Products marketed in Belgium must carry labelling and product information in French, Dutch and German.

Do you translate clinical trial documents?

Yes: protocols and amendments, informed consent forms, participant information sheets and clinical study reports. For trials under the EU CTR, the protocol and consent forms must be translated into the language of each participating member state.

Who translates pharmaceutical files?

Specialised native-language translators who work into their mother tongue, with independent revision by a second linguist.

How is confidential clinical data handled?

Under non-disclosure agreements and in line with the GDPR.

Need a professional translation?

Request a free, no-obligation quote. We reply within 2 hours during working hours.